nerd
Senior Member
- Messages
- 863
Vancassel S, Capuron L and Castanon N (2018) Brain Kynurenine and BH4 Pathways: Relevance to the Pathophysiology and Treatment of Inflammation-Driven Depressive Symptoms. Front. Neurosci. 12:499. doi: 10.3389/fnins.2018.00499
Abstract
How is this relevant?
One of the unsolved questions of the metabolic trap theory is why and how it happens and what mechanism(s) participate in the relapsing process. This study gives one possible explanation, i.e. a biopterin dysbalance and BH4 deficiency respectively. It might be possible that pathogens suppress the IDO activity directly, but I think this will be limited to certain cell types. But how can a fraction of cells cause such wide systemic issues? The scarcer a metabolic process is, the more susceptible it is to localized pathogenicity. The biopterin cycle is relatively localized to nerves and nerve liquids. It is also connected to the folate and methylation cycles. When BH4 "runs dry" at a certain locality, tryptophan can accumulate and cause the substrate inhibition of IDO1, which will not only block kynurenine synthesis but will also make the tryptophan hydroxylase more susceptible to psychological triggers and nitrosative stress.
One approach to alleviating this aspect of the pathology is the use of sepiapterin to increase the biopterin buffer. Of course, tryptophan should be avoided as a supplement. 5-HTP would be the preferable choice for serotonin support. Niacin supplementation could partially compensate for the localized intracellular deficiency. Considering that tryptophan only becomes a problem when it accumulates in a cell, LNAAs and BCAAs can support the diffusion and efflux of accumulated tryptophan from cells (10.1007/BF00238470).
It's a fitting explanation for why PEM happens. However, from my personal experience with remission, I don't think that we really push ourselves back into the trap by a lack of pacing or by psychological triggers once we are in remission. There must be something else going on. Either the normalized metabolic function triggers the lytic signaling of a virus, or another metabolite accumulates and causes the BH4 and/or tryptophan pathways to jam again.
Abstract
The prevalence of depressive disorders is growing worldwide, notably due to stagnation in the development of drugs with greater antidepressant efficacy, the continuous large proportion of patients who do not respond to conventional antidepressants, and the increasing rate of chronic medical conditions associated with an increased vulnerability to depressive comorbidities. Accordingly, better knowledge on the pathophysiology of depression and mechanisms underlying depressive comorbidities in chronic medical conditions appears urgently needed, in order to help in the development of targeted therapeutic strategies. In this review, we present evidence pointing to inflammatory processes as key players in the pathophysiology and treatment of depressive symptoms. In particular, we report preclinical and clinical findings showing that inflammation-driven alterations in specific metabolic pathways, namely kynurenine and tetrahydrobiopterin (BH4) pathways, leads to substantial alterations in the metabolism of serotonin, glutamate and dopamine that are likely to contribute to the development of key depressive symptom dimensions. Accordingly, anti-inflammatory interventions targeting kynurenine and BH4 pathways may be effective as novel treatment or as adjuvants of conventional medications rather directed to monoamines, notably when depressive symptomatology and inflammation are comorbid in treated patients. This notion is discussed in the light of recent findings illustrating the tight interactions between known antidepressant drugs and inflammatory processes, as well as their therapeutic implications. Altogether, this review provides valuable findings for moving toward more adapted and personalized therapeutic strategies to treat inflammation-related depressive symptoms.
How is this relevant?
One of the unsolved questions of the metabolic trap theory is why and how it happens and what mechanism(s) participate in the relapsing process. This study gives one possible explanation, i.e. a biopterin dysbalance and BH4 deficiency respectively. It might be possible that pathogens suppress the IDO activity directly, but I think this will be limited to certain cell types. But how can a fraction of cells cause such wide systemic issues? The scarcer a metabolic process is, the more susceptible it is to localized pathogenicity. The biopterin cycle is relatively localized to nerves and nerve liquids. It is also connected to the folate and methylation cycles. When BH4 "runs dry" at a certain locality, tryptophan can accumulate and cause the substrate inhibition of IDO1, which will not only block kynurenine synthesis but will also make the tryptophan hydroxylase more susceptible to psychological triggers and nitrosative stress.
One approach to alleviating this aspect of the pathology is the use of sepiapterin to increase the biopterin buffer. Of course, tryptophan should be avoided as a supplement. 5-HTP would be the preferable choice for serotonin support. Niacin supplementation could partially compensate for the localized intracellular deficiency. Considering that tryptophan only becomes a problem when it accumulates in a cell, LNAAs and BCAAs can support the diffusion and efflux of accumulated tryptophan from cells (10.1007/BF00238470).
It's a fitting explanation for why PEM happens. However, from my personal experience with remission, I don't think that we really push ourselves back into the trap by a lack of pacing or by psychological triggers once we are in remission. There must be something else going on. Either the normalized metabolic function triggers the lytic signaling of a virus, or another metabolite accumulates and causes the BH4 and/or tryptophan pathways to jam again.